QL1706 Plus Nab-paclitaxel +/- Bevacizumab as 1L Treatment in Recurrent or Metastatic Triple-Negative Breast Cancer: a Non-randomized, Multicenter Phase II Study
Latest Information Update: 10 Feb 2025
Price :
$35 *
At a glance
- Drugs Bevacizumab (Primary) ; Iparomlimab/tuvonralimab (Primary) ; Paclitaxel (Primary)
- Indications Triple negative breast cancer
- Focus Therapeutic Use
- 29 Jan 2025 New trial record